-
BeiGene announced that the Guangzhou biopharmaceutical production base was approved for commercial production for the first time
Time of Update: 2021-07-11
" The construction of BeiGene's Guangzhou biopharmaceutical production base complies with the existing Good Manufacturing Practices (cGMP) adopted by the US Food and Drug Administration (FDA), China National Medical Products Administration (NMPA) and European Medicines Agency (EMA) .
-
Huahai Pharmaceutical's performance fell in the first quarter, the stock price continued to fall by the limit, and some funds have "fleeed" in advance
Time of Update: 2021-07-11
Reporter | Jin MiaoEdit|Xu Yue Following the two-day limit on April 7th and 8th, on the evening of April 8th, Huahai Pharmaceutical issued 5 announcements in a row, including the pre-increasing report for the first quarter of 2021, the 2020 performance report, abnormal stock trading fluctuations, and the sale of shareholding companies.
-
Luye Pharma Announces 2020 Annual Results
Time of Update: 2021-07-11
On March 31, Luye Pharmaceutical Group released the 2020 full-year results and the latest progress in key clinical projects and commercialization . Innovative R&D-The structure of products unde
-
MassMutual Securities announces that it has completed the exercise of the over-allotment right of public development shares for its client Nature Pharmaceuticals
Time of Update: 2021-07-11
After fully exercising the over-allotment right, the total number of shares of the company's public offering increased to 5.
-
Nature Pharmaceutical announces that its underwriters have completed the exercise of the over-allotment right of public development shares
Time of Update: 2021-07-11
(the "Company") (Nasdaq: UPC) today announced that its underwriters have fully exercised the previously announced over-allotment rights for IPO shares to The public offering price of $5 shares an additional subscription of 750,000 common shares and an additional financing of $3.
-
National Class 1 anti-tumor drug Utidelon was launched
Time of Update: 2021-07-11
As the first domestic innovative epothilone anti-tumor drug independently developed by Huahao Zhongtian, the launch of Utidrolone provides an important new treatment option for Chinese patients with advanced breast cancer .
-
Gilead Sciences company Trodelvy receives FDA approval for treatment of new indications
Time of Update: 2021-07-11
Everest Medicines, a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to meeting unmet medical needs in Greater China and other Asian markets, today announced the US Food and Drug Administration (FDA) The drug Trodelvy® (generic name: sacituzumab govitecan-hziy) under Gilead Sciences (NASDAQ: GILD) is fully approved for the treatment of locally unresectable advanced or metastatic third-party patients who have received at least two lines or more of previous treatments.
-
Tianjing Bio and ABL Bio announce the completion of the first patient administration of TJ-L14B Phase 1 U.S. clinical study
Time of Update: 2021-07-11
Tolcher, the chief investigator of this phase 1 clinical study, CEO and Director of the Clinical Research Center of NEXT Oncology, said: "TJ-L14B/ABL503 has demonstrated the potential for safety and anti-tumor activity.
-
Let me ask Kanghong Pharmaceutical again: When will the Conbercept global trial release detailed control data?
Time of Update: 2021-07-10
The full name of Kanghong Pharmaceutical's PANDA trial is "a multi-center, double-blind, randomized, dose-range trial to evaluate the efficacy and safety of Conbercept ophthalmic injection in the treatment of neovascular age-related macular degeneration" clinical trial In the project, the control group used Bayer's aflibercept.
-
Sanofi China's first global research institute opened
Time of Update: 2021-07-10
He said: "The opening of Sanofi China Research Institute will promote biological The collaboration between pharmaceutical companies, Chinese academia, scientific research circles and clinical institutions has deepened to promote the development of an innovative ecosystem and help Suzhou build a new highland for the concentration of the biopharmaceutical industry .
-
Lonza and Junshi Biotech signed a strategic cooperation agreement to comprehensively accelerate the development and production of biopharmaceuticals
Time of Update: 2021-07-10
At the same time, Lonza will rely on its biological product production network spanning three continents and unified global quality operation standards to help Junshi Biology accelerate the pace of expansion in the international market, and help China's local innovations to reach the world .
-
19 pharmaceutical companies including Hengrui and Buchang were punished by the penetrating "account audit" of the Ministry of Finance
Time of Update: 2021-07-10
According to Article 42 of the "Accounting Law of the People's Republic of China", the Ministry of Finance imposed administrative penalties on 19 pharmaceutical companies inspected by relevant regulatory bureaus of the Ministry of Finance .
-
Nuocheng Jianhua and Jinan University reached a school-enterprise strategic cooperation
Time of Update: 2021-07-10
We expect that both parties will continue to deepen the integration of production and education, jointly accelerate the development and transformation of innovative drugs, and promote the development of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area .
-
Benchmark Medical and iKang Guobin jointly promote the cause of early screening for bladder cancer
Time of Update: 2021-07-10
The two parties will give full play to their respective advantages in products and channels, establish an open and sustainable development of a large health field urinary tract tumor diagnosis and treatment ecosystem, and jointly promote the cause of early screening and early diagnosis of urothelial cancer in China, and benefit more people.
-
BeiGene Announces Interim Analysis Results of RATIONALE 303 Clinical Trial of Baizean for the Treatment of Second-line or Third-line Non-Small Cell Lung Cancer
Time of Update: 2021-07-10
Professor Zhou Caicun, Director of Oncology Department of Shanghai Pulmonary Hospital and Director of Tongji University Cancer Institute, said: “According to the results of the RATIONALE 303 test, compared with the standard treatment of docetaxel, Baizean® can significantly prolong the median OS of all patients to More than 5 months, and bring consistent overall survival benefits for all patients, regardless of PD-L1 expression .
-
Danaher Helps Boao Lecheng Pioneer Zone to Realize the "Triple Synchronization" of Technology, Equipment and Medicine
Time of Update: 2021-07-10
Wei Chunyan, Vice President of Chinese Government Affairs of Danaher, said that this time, Danaher brought a group of innovative products to participate in Boao Lecheng Phase II "Never Ending" International Pharmaceutical Equipment Exhibition, and provided medical solutions in multiple fields, also in order to respond positively.
-
Deqi Pharmaceutical ATG-010 combined with ATG-008 has a significant synergistic effect in the treatment of triple-strike DLBCL
Time of Update: 2021-07-10
announced that the company will announce ATG-010 (selinexor, XPO1 inhibitor) combined with ATG-008 at the 2021 American Society for Cancer Research (AACR) annual meeting (onatasertib, mTORC1/2 inhibitor) Preclinical data on the synergistic effect of triple-strike diffuse large B-cell lymphoma (DLBCL) .
-
Moutai 1.9 billion hospitals!
Time of Update: 2021-07-10
According to media reports, Moutai, which has a market value of 2 trillion yuan, is about to open a hospital for the establishment of schools and airports .
Moutai Hospital, which is about to operate in June, will start recruiting in the near future .
-
The first "serious" untrustworthy drug sourcing appeared, and the sales of a product of Yuheng Pharmaceutical was suspended in Zhejiang due to commercial bribery
Time of Update: 2021-07-10
According to the "Notice", A-share listed company Yuheng Pharmaceutical's product Lugua Polypeptide Injection has been involved in commercial bribery in Zhejiang Province.
-
Antibody and recombinant protein drug CDMO Haoyang Biotechnology completes over 80 million yuan in Series A financing
Time of Update: 2021-07-10
Constructed a high-expressing stable cell line and won the first domestic IND approval for a biosimilar drug of dulaglutide On March 24, 2021, a piece of news exploded in the medical CDMO circle.
